Sherrie Constantine

Sherrie Constantine serves as a key procurement professional within the CDC Office of Acquisition Services, supporting the agency’s mission to safeguard public health through strategic acquisition of critical biomedical and diagnostic capabilities. She manages complex contracting actions for laboratory diagnostics, analytical instrumentation, and data infrastructure essential to disease surveillance and outbreak response. Her work ensures timely access to high-integrity scientific tools and services that enable CDC’s rapid deployment of public health interventions across the nation. Her portfolio primarily involves full and open competitions under FAR Part 15, with a focus on performance-based contracting for mission-critical health technologies. Constantine maintains longstanding relationships with leading providers in the public health ecosystem, including General Dynamics Information Technology, Cepheid, MRIGLOBAL, GlaxoSmithKline, and New York City Health & Hospitals Corp. These partnerships center on the procurement of in-vitro diagnostic systems, advanced laboratory equipment, biotechnology research services, and secure computing infrastructure. Her contracting approach emphasizes vendor reliability, regulatory compliance, and technical scalability, ensuring that acquired solutions meet stringent CDC standards for accuracy, interoperability, and biosafety. Her procurement patterns reflect a strong preference for full and open competition, with 91.7% of awards issued without set-asides, indicating a focus on technical excellence and market-wide competition. Only 8.3% of awards are designated as total small business set-asides under FAR 19.5, suggesting targeted but limited use of socioeconomic programs, primarily when market capabilities align with small business strengths in niche diagnostic or analytical domains. Her primary NAICS focus includes in-vitro diagnostic substance manufacturing (325413) and analytical laboratory instrument manufacturing (334516), reflecting deep expertise in procuring molecular diagnostics, PCR systems, and lab automation technologies. She also routinely acquires biotechnology R&D services (541714) and data infrastructure solutions (518210), demonstrating specialized knowledge in the intersection of public health science and commercial technology innovation.